Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
95
Recruiting, any sponsor type, condition "pulmonary arterial hypertension"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed464
95 trials
Showing 1 to 25, recently updated first.
- Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward)Pivotal-lookingRecruiting
Foresee Pharmaceuticals Co., Ltd.Industry
NCT06475781 · 126 participants (planned) · Start Mar 1, 2025 · Primary completion Feb 2028
Drug: Mirivadelgat; placebo · For: Group 3 Pulmonary Hypertension
Sites: Banja Luka, Bosnia and Herzegovina; Sarajevo, Bosnia and Herzegovina; Tbilisi, Georgia · 15 sites in all
National Institutes of Health Clinical Center (CC)NIH
NCT01712620 · 70 participants (planned) · Start Jan 10, 2014 · Primary completion Dec 31, 2031
Drug: Spironolactone; Placebo · For: Pulmonary Arterial Hypertension
Sites: Bethesda, Maryland
AllRock Bio, Inc.Industry
NCT07175038 · 40 participants (planned) · Start Oct 1, 2025 · Primary completion Mar 2027
Drug: ROC-101 · For: Pulmonary Arterial Hypertension (PAH); Pulmonary Hypertension, Interstitial Lung Disease
Sites: Phoenix, Arizona; Rancho Cordova, California; Aurora, Colorado · 25 sites in all
- An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Pivotal-lookingRecruiting
Insmed IncorporatedIndustry
NCT07234032 · 344 participants (planned) · Start Jul 20, 2026 · Primary completion Jan 22, 2031
Drug: Treprostinil Palmitil Inhalation Powder; Placebo · For: Pulmonary Hypertension; Interstitial Lung Disease
Sites: Naples, Florida; Bend, Oregon; Prague, Czechia · 12 sites in all
University of AlbertaAcademic, hospital or other
NCT07140484 · 27 participants (planned) · Start Oct 6, 2025 · Primary completion Jan 1, 2029
Drug: Sotatercept · For: Pulmonary Artery Hypertension
Sites: Edmonton, Canada
- The Effect of Additive On-Demand Sildenafil vs. Dextrose Candy on Maximum Exercise Capacity in Pulmonary Arterial HypertensionPivotal-lookingRecruiting
Silvia UlrichAcademic, hospital or other
NCT07824674 · 20 participants (planned) · Start Oct 26, 2026 · Primary completion Apr 2028
Drug: Dextrose; Sildenafil 20mg · For: Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Sites: Zurich, Switzerland
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07600723 · 30 participants (planned) · Start Oct 8, 2026 · Primary completion Apr 3, 2028
Drug: Sotatercept; Background PAH Therapy · For: Pulmonary Arterial Hypertension
Sites: Hyderabad, India; Belagavi, India; Chennai, India
Meshalkin Research Institute of Pathology of CirculationResearch network
NCT07914933 · 50 participants (planned) · Start Apr 29, 2025 · Primary completion Nov 2027
Drug: Infusion of levosimendan; Placebo infusion "Soluvit" · For: LEVOSIMENDAN; PULMONARY THROMBOENDARTERECTOMY; Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and 1 more
Sites: Novosibirsk, Russia
- A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionPivotal-lookingRecruiting
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT05179876 · 280 participants (planned) · Start May 4, 2022 · Primary completion Jan 31, 2027
Drug: Macitentan; Selexipag and 1 more · For: Hypertension, Pulmonary
Sites: Minsk, Belarus; Leuven, Belgium; Sofia, Bulgaria · 45 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05587712 · 42 participants (planned) · Start Jan 19, 2023 · Primary completion Sep 21, 2028
Drug: Sotatercept · For: Pulmonary Arterial Hypertension
Sites: Los Angeles, California; Palo Alto, California; San Francisco, California · 35 sites in all
35Pharma Inc., a GSK companyIndustry
NCT07143448 · 90 participants (planned) · Start Aug 19, 2026 · Primary completion Mar 2028
Drug: HS235 · For: Pulmonary Arterial Hypertension
Sites: Tampa, Florida; Boston, Massachusetts; Providence, Rhode Island · 7 sites in all
- HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection FractionPivotal-lookingRecruiting
35Pharma Inc., a GSK companyIndustry
NCT07123779 · 126 participants (planned) · Start Oct 21, 2026 · Primary completion Jan 2029
Drug: HS235 · For: Pulmonary Hypertension; Heart Failure With Preserved Ejection Fraction
Sites: Kansas City, Missouri; Greenville, South Carolina; Dallas, Texas
China National Center for Cardiovascular DiseasesGovernment (non-federal)
NCT07667829 · 75 participants (planned) · Start Aug 19, 2026 · Primary completion Dec 31, 2028
Drug: Norepinephrine; Dopamine and 1 more · For: Pulmonary Arterial Hypertension (PAH); Chronic Thromboembolic Pulmonary Hypertension (CTEPH); Hypertension, Pulmonary
Sites: Beijing, China; Guangzhou, China; Wuhan, China
- De-implementing Inhaled Nitric Oxide for Congenital Diaphragmatic HerniaPivotal-lookingRecruiting
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT05213676 · 900 participants (planned) · Start Nov 1, 2025 · Primary completion Oct 31, 2030
Drug: Inhaled Nitric Oxide (iNO) use · For: Congenital Diaphragmatic Hernia
Sites: Birmingham, Alabama; Little Rock, Arkansas; Irvine, California · 19 sites in all
- Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I PatientsPivotal-lookingRecruiting
AOP Orphan Pharmaceuticals AGIndustry
NCT06317805 · 110 participants (planned) · Start Dec 6, 2023 · Primary completion Jun 2027
Drug: Generic treprostinil sodium + Standard of Care (Double Oral); Standard of Care - Double Oral · For: Pulmonary Arterial Hypertension
Sites: Bahía Blanca, Argentina; Buenos Aires, Argentina; La Plata, Argentina · 28 sites in all
- Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAHPivotal-lookingRecruiting
AOP Orphan Pharmaceuticals AGIndustry
NCT06350032 · 20 participants (planned) · Start Jul 31, 2024 · Primary completion Nov 2028
Drug: preservative-free parenteral treprostinil · For: Pulmonary Arterial Hypertension
Sites: Vienna, Austria; Paris, France; Budapest, Hungary · 5 sites in all
- A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Pivotal-lookingRecruiting
NS Pharma, Inc.Industry
NCT07441278 · 177 participants (planned) · Start Sep 28, 2026 · Primary completion Sep 14, 2028
Drug: NS-863 Low Dose; NS-863 High Dose · For: Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Sites: Knoxville, Tennessee; Kitakyushu, Japan
The First Affiliated Hospital with Nanjing Medical UniversityAcademic, hospital or other
NCT07847710 · 81 participants (planned) · Start Sep 30, 2026 · Primary completion Mar 1, 2028
Drug: Retlirafusp alfa; Famitinib malate and 3 more · For: Intrahepatic Cholangiocarcinoma (Icc); Neoadjuvant Therapy
Sites: Nanjing, China
- Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)Pivotal-lookingRecruiting
NS Pharma, Inc.Industry
NCT07441200 · 135 participants (planned) · Start Sep 29, 2026 · Primary completion Aug 1, 2028
Drug: NS-863 Low Dose; NS-863 High Dose and 1 more · For: Pulmonary Arterial Hypertension
Sites: Kitakyushu, Japan
- Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung DiseaseRecruiting
Tectonic Operating Company, Inc.Industry
NCT07473700 · 25 participants (planned) · Start Oct 30, 2026 · Primary completion Nov 21, 2027
Drug: TX000045 · For: Hypertension, Pulmonary; Lung Diseases, Interstitial
Sites: Phoenix, Arizona; San Francisco, California; Boise, Idaho · 16 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07318597 · 99 participants (planned) · Start May 6, 2026 · Primary completion Feb 27, 2028
Drug: REGN13335; Placebo · For: Pulmonary Arterial Hypertension (PAH)
Sites: Aurora, Colorado; Boston, Massachusetts; Omaha, Nebraska · 33 sites in all
- Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT ImagingPivotal-lookingRecruiting
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT07613099 · 210 participants (planned) · Start Sep 18, 2026 · Primary completion May 26, 2031
Drug: [18F]FAPI-74 · For: Allogeneic Stem Cell Transplantation; Lung Allograft Transplantation; Interstitial Lung Disease and 3 more
Sites: Bethesda, Maryland
- Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Pivotal-lookingRecruiting
Insmed IncorporatedIndustry
NCT07179380 · 344 participants (planned) · Start Jan 7, 2026 · Primary completion Dec 30, 2028
Drug: Treprostinil Palmitil Inhalation Powder; Placebo · For: Pulmonary Hypertension; Interstitial Lung Disease
Sites: Phoenix, Arizona; Fresno, California; Los Angeles, California · 186 sites in all
Ain Shams UniversityAcademic, hospital or other
NCT07850934 · 52 participants (planned) · Start Jul 1, 2025 · Primary completion Nov 1, 2026
Drug: Melatonin · For: Congenital Peumonia; Persistent Pulmonary Hypertension of Newborn; Congenital Diaphragmatic Hernia
Sites: Cairo, Egypt
National Cancer Institute (NCI)NIH
NCT05286814 · 70 participants (planned) · Start Oct 24, 2022 · Primary completion Dec 31, 2027
Drug: Dexamethasone; PDS01ADC and 1 more · For: Metastatic Colorectal Cancer (Mcrc); Intrahepatic Cholangiocarcinoma (Icc); Intrahepatic Bile Duct Cancer and 10 more
Sites: Bethesda, Maryland
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.